Alpha Cognition Inc. Common Stock (ACOG)
$
4.84
-0.34 (-7.02%)
Key metrics
Financial statements
Free cash flow per share
-0.9898
Market cap
71.9 Million
Price to sales ratio
9.6800
Debt to equity
0
Current ratio
6.6911
Income quality
0.8131
Average inventory
2.7 Million
ROE
-0.5260
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
News
businesswire.com
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition, Inc. (the “Company”, “we”, “us” and “ours”) (NASDAQ: ACOG), a commercial-stage neuroscience company focused on advancing treatments for cognitive and neuropsychiatric disorders, today announced a corporate update outlining strategic priorities for 2026 and summarizing key accomplishments achieved in 2025. Management Commentary, Michael McFadden, Chief Executive Officer “We are pleased with the transition from the.
zacks.com
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
seekingalpha.com
Alpha Cognition Inc. (ACOG) Discusses Commercial Adoption Metrics and Market Opportunity in Long-Term Care Transcript
zacks.com
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
zacks.com
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.31 per share a year ago.
seekingalpha.com
Alpha Cognition Inc. ( ACOG ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Henry Du - VP of Finance & Accounting and Interim CFO Michael McFadden - CEO & Director Lauren D'Angelo - Chief Operating Officer Conference Call Participants Boris Peaker David Storms - Stonegate Capital Partners, Inc., Research Division Presentation Operator Greetings. Welcome to Alpha Cognition's Earnings Conference Call.
businesswire.com
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical insights on cholinesterase inhibitors and ZUNVEYL® (Benzgalantamine) at two upcoming scientific meetings: the American Society of Consultant Pharmacists (ASCP) Annual Meeting (October 23–25, 2025) and the Neuroscienc.
businesswire.com
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced the pricing of its oversubscribed underwritten public offering of 5,600,000 common shares (or pre-funded warrants in lieu thereof), at a public offering price of $6.25 per share. The gross proceeds of the offering are approximately $35.0 million, befor.
businesswire.com
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (the “Company”), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that it is proposing to offer and sell its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares, in an underwritten public offering. In addition, the Company intends to grant the underwrite.
businesswire.com
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative diseases, today announced that Chief Executive Officer Michael McFadden will present at two prominent healthcare investor conferences this September. Cantor Global Healthcare Conference 2025 Date/Time: Friday, September 5, 7:00 a.m. ET H.C. Wainwright & Co. Healthcare Conference 2025 Date/.
See all news
